PURPOSE: We have demonstrated that toxicities are acceptable with total marrow irradiation (TMI) at 16 Gy without chemotherapy or TMI at 12 Gy and the reduced intensity regimen of fludarabine/melphalan in patients undergoing hematopoietic cell transplantation (HCT). This article reports results of a study of TMI combined with higher intensity chemotherapy regimens in 2 phase I trials in patients with advanced acute myelogenous leukemia or acute lymphoblastic leukemia (AML/ALL) who would do poorly on standard intent-to-cure HCT regimens. METHODS AND MATERIALS: Trial 1 consisted of TMI on Days -10 to -6, etoposide (VP16) on Day -5 (60 mg/kg), and cyclophosphamide (CY) on Day -3 (100 mg/kg). TMI dose was 12 (n=3 patients), 13.5 (n=3 patients), and 15 (n=6 patients) Gy at 1.5 Gy twice daily. Trial 2 consisted of busulfan (BU) on Days -12 to -8 (800 μM min), TMI on Days -8 to -4, and VP16 on Day -3 (30 mg/kg). TMI dose was 12 (n=18) and 13.5 (n=2) Gy at 1.5 Gy twice daily. RESULTS: Trial 1 had 12 patients with a median age of 33 years. Six patients had induction failures (IF), and 6 had first relapses (1RL), 9 with leukemia blast involvement of bone marrow ranging from 10%-98%, 5 with circulating blasts (24%-85%), and 2 with chloromas. No dose-limiting toxicities were observed. Eleven patients achieved complete remission at Day 30. With a median follow-up of 14.75 months, 5 patients remained in complete remission from 13.5-37.7 months. Trial 2 had 20 patients with a median age of 41 years. Thirteen patients had IF, and 5 had 1RL, 2 in second relapse, 19 with marrow blasts (3%-100%) and 13 with peripheral blasts (6%-63%). Grade 4 dose-limiting toxicities were seen at 13.5 Gy (stomatitis and hepatotoxicity). Stomatitis was the most frequent toxicity in both trials. CONCLUSIONS: TMI dose escalation to 15 Gy is possible when combined with CY/VP16 and is associated with acceptable toxicities and encouraging outcomes. TMI dose escalation is not possible with BU/VP16 due to dose-limiting toxicities. Future efforts will focus on whether further dose escalation with CY/VP16 is safe, with the goal of improving disease control in this high-risk population.
PURPOSE: We have demonstrated that toxicities are acceptable with total marrow irradiation (TMI) at 16 Gy without chemotherapy or TMI at 12 Gy and the reduced intensity regimen of fludarabine/melphalan in patients undergoing hematopoietic cell transplantation (HCT). This article reports results of a study of TMI combined with higher intensity chemotherapy regimens in 2 phase I trials in patients with advanced acute myelogenous leukemia or acute lymphoblastic leukemia (AML/ALL) who would do poorly on standard intent-to-cure HCT regimens. METHODS AND MATERIALS: Trial 1 consisted of TMI on Days -10 to -6, etoposide (VP16) on Day -5 (60 mg/kg), and cyclophosphamide (CY) on Day -3 (100 mg/kg). TMI dose was 12 (n=3 patients), 13.5 (n=3 patients), and 15 (n=6 patients) Gy at 1.5 Gy twice daily. Trial 2 consisted of busulfan (BU) on Days -12 to -8 (800 μM min), TMI on Days -8 to -4, and VP16 on Day -3 (30 mg/kg). TMI dose was 12 (n=18) and 13.5 (n=2) Gy at 1.5 Gy twice daily. RESULTS: Trial 1 had 12 patients with a median age of 33 years. Six patients had induction failures (IF), and 6 had first relapses (1RL), 9 with leukemia blast involvement of bone marrow ranging from 10%-98%, 5 with circulating blasts (24%-85%), and 2 with chloromas. No dose-limiting toxicities were observed. Eleven patients achieved complete remission at Day 30. With a median follow-up of 14.75 months, 5 patients remained in complete remission from 13.5-37.7 months. Trial 2 had 20 patients with a median age of 41 years. Thirteen patients had IF, and 5 had 1RL, 2 in second relapse, 19 with marrow blasts (3%-100%) and 13 with peripheral blasts (6%-63%). Grade 4 dose-limiting toxicities were seen at 13.5 Gy (stomatitis and hepatotoxicity). Stomatitis was the most frequent toxicity in both trials. CONCLUSIONS:TMI dose escalation to 15 Gy is possible when combined with CY/VP16 and is associated with acceptable toxicities and encouraging outcomes. TMI dose escalation is not possible with BU/VP16 due to dose-limiting toxicities. Future efforts will focus on whether further dose escalation with CY/VP16 is safe, with the goal of improving disease control in this high-risk population.
Authors: George Somlo; Ricardo Spielberger; Paul Frankel; Chatchada Karanes; Amrita Krishnan; Pablo Parker; Leslie Popplewell; Firoozeh Sahebi; Neil Kogut; David Snyder; An Liu; Timothy Schultheiss; Stephen Forman; Jeffrey Y C Wong Journal: Clin Cancer Res Date: 2010-11-03 Impact factor: 12.531
Authors: Michel Duval; John P Klein; Wensheng He; Jean-Yves Cahn; Mitchell Cairo; Bruce M Camitta; Rammurti Kamble; Edward Copelan; Marcos de Lima; Vikas Gupta; Armand Keating; Hillard M Lazarus; Mark R Litzow; David I Marks; Richard T Maziarz; David A Rizzieri; Gary Schiller; Kirk R Schultz; Martin S Tallman; Daniel Weisdorf Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: J A Peñagarícano; M Chao; F Van Rhee; E G Moros; P M Corry; V Ratanatharathorn Journal: Bone Marrow Transplant Date: 2010-10-11 Impact factor: 5.483
Authors: Ricardo Spielberger; Patrick Stiff; William Bensinger; Teresa Gentile; Daniel Weisdorf; Tarun Kewalramani; Thomas Shea; Saul Yanovich; Keith Hansen; Stephen Noga; John McCarty; C Frederick LeMaistre; Eric C Sung; Bruce R Blazar; Dieter Elhardt; Mon-Gy Chen; Christos Emmanouilides Journal: N Engl J Med Date: 2004-12-16 Impact factor: 91.245
Authors: R A Brown; S N Wolff; J W Fay; L Pineiro; R H Collins; J P Lynch; D Stevens; J Greer; R H Herzig; G P Herzig Journal: Leuk Lymphoma Date: 1996-07
Authors: Anthony Stein; Joycelynne Palmer; Ni-Chun Tsai; Monzr M Al Malki; Ibrahim Aldoss; Haris Ali; Ahmed Aribi; Len Farol; Chatchada Karanes; Samer Khaled; An Liu; Margaret O'Donnell; Pablo Parker; Anna Pawlowska; Vinod Pullarkat; Eric Radany; Joseph Rosenthal; Firoozeh Sahebi; Amandeep Salhotra; James F Sanchez; Tim Schultheiss; Ricardo Spielberger; Sandra H Thomas; David Snyder; Ryotaro Nakamura; Guido Marcucci; Stephen J Forman; Jeffrey Wong Journal: Biol Blood Marrow Transplant Date: 2017-01-10 Impact factor: 5.742
Authors: Y S Jethava; S Sica; B Savani; F Socola; M Jagasia; M Mohty; A Nagler; A Bacigalupo Journal: Bone Marrow Transplant Date: 2017-05-15 Impact factor: 5.483
Authors: E Todisco; F Ciceri; C Boschini; F Giglio; A Bacigalupo; F Patriarca; I Donnini; E P Alessandrino; W Arcese; A P Iori; P Marenco; I Cavattoni; P Chiusolo; E Terruzzi; L Castagna; A Santoro; A Bosi; E Oldani; B Bruno; F Bonifazi; A Rambaldi Journal: Bone Marrow Transplant Date: 2017-01-09 Impact factor: 5.483
Authors: Mitchell Sabloff; Saurabh Chhabra; Tao Wang; Caitrin Fretham; Natasha Kekre; Allistair Abraham; Kehinde Adekola; Jeffery J Auletta; Christopher Barker; Amer M Beitinjaneh; Christopher Bredeson; Jean-Yves Cahn; Miguel Angel Diaz; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Usama Gergis; Eva Guinan; Betty K Hamilton; Shahrukh Hashmi; Peiman Hematti; Gerhard Hildebrandt; Leona Holmberg; Sanghee Hong; Hillard M Lazarus; Rodrigo Martino; Lori Muffly; Taiga Nishihori; Miguel-Angel Perales; Jean Yared; Shin Mineishi; Edward A Stadtmauer; Marcelo C Pasquini; Alison W Loren Journal: Biol Blood Marrow Transplant Date: 2019-08-29 Impact factor: 5.742
Authors: Taiki Magome; Jerry Froelich; Yutaka Takahashi; Luke Arentsen; Shernan Holtan; Michael R Verneris; Keenan Brown; Akihiro Haga; Keiichi Nakagawa; Jennifer L Holter Chakrabarty; Sebastian Giebel; Jeffrey Wong; Kathryn Dusenbery; Guy Storme; Susanta K Hui Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-06 Impact factor: 7.038
Authors: Darren Zuro; Stefano Vagge; Sara Broggi; Stefano Agostinelli; Yutaka Takahashi; Jamison Brooks; Paulina Leszcynska; An Liu; Claudio Zucchetti; Simonetta Saldi; Chunhui Han; Mauro Cattaneo; Sebastian Giebel; Marc Andre Mahe; James F Sanchez; Parham Alaei; Chiara Anna; Kathryn Dusenbery; Antonio Pierini; Guy Storme; Cynthia Aristei; Jeffrey Y C Wong; Susanta Hui Journal: Radiother Oncol Date: 2019-08-14 Impact factor: 6.280
Authors: Dennis Stanley; Kristen McConnell; Zohaib Iqbal; Ashlyn Everett; Jonathan Dodson; Kimberly Keene; Andrew McDonald Journal: Cureus Date: 2021-06-14